InnoCan Pharma Corporation (CSE:INNO)

Market Cap	14.17M -75.6%
Revenue (ttm)	35.29M -17.0%
Net Income	-2.11M
EPS	-0.47
Shares Out	4.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900
Open	3.290
Previous Close	3.200
Day's Range	3.150 - 3.300
52-Week Range	3.010 - 21.000
Beta	-0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About InnoCan Pharma

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vag...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2017
• Employees: 5
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2025, InnoCan Pharma's revenue was $26.61 million, a decrease of -9.60% compared to the previous year's $29.44 million. Losses were -$1.12 million, -38.71% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error